Propanc Biopharma, Inc. (PPCB): debt financing — Propanc Biopharma issues $67,860 convertible note with 35% conversion discount to 1800 Diagonal Lending

Propanc Biopharma, Inc.

Principal $67,860 for net $58,000; matures Apr 16, 2026; 15% one-time interest.
Conversion at 65% of lowest trading price in prior 10 days (35% discount); dilution risk.
Payments: $39,019.50 on Dec 15, 2025; then $9,754.88 on Jan 15, Feb 15, Mar 15, Apr 15, 2026.
Default triggers immediate acceleration; includes failure to pay, maintain OTC listing, or SEC reporting.
Proceeds for general working capital; note issued under Regulation D, not registered.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Propanc Biopharma, Inc. incurred convertible notes of $67,860.00 with an investor at one-time interest charge of fifteen percent (15%) maturing April 16, 2026.

Instrument: convertible notes
Principal: $67,860.00
Counterparty: an investor
Rate: one-time interest charge of fifteen percent (15%)
Maturity: April 16, 2026
Event: incurrence

Exact text from the filing

with an investor (the “Investor”) pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $67,860.00 (the “Note”), for a purchase price of $58,000. The Company intends to use the net proceeds therefrom for general working capital purposes. The maturity date of the Note is April

View on SEC.gov

Browse all debt financings →

Propanc Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-016719

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.